Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer.
Oluwadunni E EmilojuMichael StorandtTyler ZemlaNguyen H TranKrishan R JethwaAmit MahipalJessica L MitchellCornelius A ThielsKellie MathisRobert R McWilliamsJoleen M HubbardFrank A SinicropeQian ShiZhaohui JinPublished in: JCO precision oncology (2024)
Routine ctDNA monitoring for MRD detection has been adopted in clinical practice; however, 84% of ctDNA assays performed did not result in a change in clinical management. This suggests the need for further clinical research data to guide routine clinical use of ctDNA MRD testing in CRC.